The EVOID-AS trial is a double-blind, placebo-controlled, randomized trial designed to test whether evogliptin, a dipeptidyl peptidase 4 inhibitor, retards progression of aortic valve calcification and hemodynamic severity in patients with mild to moderate calcific aortic stenosis, which could address the critical unmet need for a medical therapy to prevent or delay AS progression.
No medical therapy has been proven effective for preventing or delaying aortic stenosis progression, and aortic valve replacement remains the only treatment for severe AS.
EVOID-AS is designed as a randomized, double-blind, placebo-controlled trial of evogliptin 10 mg daily versus placebo for 2 years in patients with mild or moderate native calcific AS.
The trial's primary end point is change in aortic valve calcification measured by cardiac computed tomography after 2 years of therapy.
Secondary end points include progression of AS hemodynamic severity by echocardiography and time to aortic valve intervention, with secondary safety end points covering adverse events.
The trial schedule includes clinical follow-up every 3 months, with imaging and laboratory testing at baseline, 1 year, and 2 years; enrollment began in June 2022 and completion is expected in 2028.
This is a design paper; no efficacy or safety results are reported.
Aortic stenosis is a condition where the heart's aortic valve becomes calcified and narrowed. Currently, the only treatment for severe disease is replacing the valve, and no medication has been proven to slow the disease, despite several trials. This paper describes the design of a new trial, EVOID-AS, which tests whether evogliptin, a diabetes-type drug in the DPP-4 inhibitor class, can slow valve calcification in people with mild to moderate aortic stenosis. The trial plans to enroll 580 patients at more than 40 sites in the US and Canada. Participants will be randomly assigned, with neither patients nor investigators knowing which, to take evogliptin 10 mg or a placebo daily for two years. Heart CT scans will measure the amount of calcium in the valve, and ultrasound of the heart will assess how severe the narrowing is. Safety and adverse events will also be tracked. This paper reports no results, since the trial is ongoing and expected to finish in 2028. This research is aimed at finding out whether a medication could one day delay the progression of aortic stenosis and potentially postpone the need for valve replacement, but it is not yet known whether evogliptin works.
Padang R, Hodara R, Jan M, Jain R, Postalian A, Zweig B, et al.. (2026). Efficacy and Safety of Evogliptin in Mild to Moderate Calcific Aortic Valve Stenosis: The EVOID-AS Trial Rationale and Study Design.. Mayo Clinic proceedings. https://doi.org/10.1016/j.mayocp.2026.08.017